2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s